Cite

Figure 1

Unadjusted comparisons of mortality, TLR and MACE at 4 years according to the type of the stent in patients with unprotected left main coronary artery disease. Curves represent Kaplan-Meier failure function.
Unadjusted comparisons of mortality, TLR and MACE at 4 years according to the type of the stent in patients with unprotected left main coronary artery disease. Curves represent Kaplan-Meier failure function.

SYNTAX, SYNTAX II (for PCI and CABG, with respective predicted mortality) and EuroSCORE II scores of patients with unprotected left main coronary artery disease according to the stent strategy

Balloon-expandable stents Self-apposing stents Total p value
SYNTAX 23.5 (16.5–30.5) 17.5 (11–25.5) 21 (13–29) 0.004
SYNTAX-2 PCI 34.1 (25.6–45.4) 28.9 (22.1–40.7) 32.2 (23.6–43.6) 0.04
Estimated PCI mortality 9.8 (4.9–22.7) 6.2 (3.6–15.9) 8.3 (4.1–19.9) 0.03
SYNTAX-2 CABG 31.5 (23.3–40.9) 25.3 (16.4–33.6) 28.9 (19.4–38) 0.01
Estimated CABG mortality 7.7 (3.9–16.2) 4.6 (2.2–10.3) 6.2 (2.9–13.6) 0.01
EUROSCORE II 1.6 (1–3.3) 1.1 (0.8–2.5) 1.3 (0.9–2.8) 0.1

Angiographic findings of patients with unprotected left main coronary artery disease according to the type of implanted stent (LM – left main; LAD – left anterior descending artery; LCX – left circumflex artery; RCA – right coronary artery)

Balloon-expandable stents Self-apposing stents Total p value
Arterial access site
Radial 16 (19.1) 18 (29) 34 (23.3) 0.2
Femoral 68 (80.9) 44 (71) 112 (76.6) 0.2
Left main lesion localization
Ostial 10 (11.9) 0 (0) 10 (6.9)
Middle segment 1 (1.2) 0 (0) 1 (0.7)
Distal 58 (69) 54 (87.1) 112 (76.7)
Ostial and distal 1 (1.2) 3 (4.8) 4 (2.7)
Whole length 14 (16.7) 5 (8.1) 19 (13) 0.009
Bifurcation 63 (75) 52 (83.9) 115 (78.8) 0.2
Trifurcation 21 (25) 10 (16.1) 31 (21.2) 0.2
Other lesions
None 24 (28.6) 25 (40.3) 49 (33.6)
One vessel 27 (32.1) 17 (27.4) 44 (30.1)
Two vessels 23 (27.4) 16 (25.8) 39 (26.7)
Three vessels 10 (11.9) 4 (6.5) 14 (9.6) 0.4
Chronic total occlusion 17 (20.2) 14 (22.6) 31 (21.2) 0.8
LAD ostium involved 45 (53.6) 50 (80.6) 95 (65.1) 0.001
LCX ostium involved 36 (42.9) 24 (38.7) 60 (41.1) 0.7
LAD non-ostial lesion 41 (48.8) 23 (37.1) 64 (43.8) 0.2
LCX non-ostial lesion 27 (312.1) 13 (21) 40 (27.4) 0.2
RCA lesion 28 (33.3) 20(32.3) 48 (32.9) 0.5
Left main lesion characteristics
Diffuse lesion 49 (5.3) 27 (43.5) 76 (52.1) 0.09
Eccentric lesion 64 (76.2) 43 (69.4) 107 (73.3) 0.4
Calcified lesion 29 (34.5) 14 (22.6) 43 (29.4) 0.1
Ulcerated lesion 21 (25) 15 (24.2) 26 (25.7) 0.5
Carina involved 4 (4.8) 5 (8.1) 9 (6.2) 0.5
Medina classification (only distal Left main lesions)
1/1/1 22 (30.1) 12 (19.4) 34 (25.2)
1/0/0 17 (23.3) 6 (9.7) 23 (17.1)
1/1/0 10 (13.7) 6 (9.7) 16 (11.9)
1/0/1 6 (8.2) 3 (4.8) 6 (6.7)
0/1/0 11 (15.1) 26 (41.9) 37 (27.4)
0/1/1 4 (5.5) 6 (9.8) 10 (7.4)
0/0/1 3 (4.1) 3 (4.8) 6 (4.4) 0.01
True bifurcation (1/1/1, 0/1/1) 26 (35.6) 18 (29) 44 (32.6) 0.5
Left main take-off angle >700 22 (32.8) 22 (37.9) 44 (35.2) 0.6
Bifurcation angle
>90 degrees 5 (8.1) 7 (12.1) 12 (10)
70–90 24 (38.7) 24 (41.4) 48 (40)
45–69 11 (17.7) 10 (17.2) 21 (17.5)
<45 22 (35.5) 17 (29.3) 39 (32.5) 0.8
LM stenosis, % (median, IQR) 67 (45–89) 30 (11–57) 55 (20–80) <0.001
LAD stenosis, % (median, IQR) 83 (58–90) 86 (71–93) 85 (66–92) 0.006
LCX stenosis, % (median, IQR) 71 (43–84) 63 (18–86) 70 (30–86) 0.4

Procedural outcomes and post-procedural complications according to the type of implanted stent in patients with unprotected left main coronary artery disease (LM – left main; SB – side branch; TIA – transient ischemic attack; PCI – percutaneous coronary intervention; CIN – contrast induced nephropathy)

Balloon-expandable stents Self-apposing stents Total p value
Unaffected LM ostium covered by implanted stent 12 (14.3) 6 (9.7) 18 (13.3) 0.4
LM lesion covered 84 (100) 60 (96.8) 133 (98.5) 0.2
SB residual stenosis
None 50 (67.5) 36 (58.1) 83 (62.4)
<50% 17 (23) 21 (33.9) 38 (28.6)
>50% 7 (9.5) 5 (8) 12 (9) 0.4
Procedural success 81 (96.4) 57 (91.9) 138 (94.5) 0.3
Complete revascularization 63 (75) 46 (74) 109 (74.7) 0.5
TIMI flow at the of the procedure
1 1 (1.2) 3 (4.8) 4 (2.7)
2 3 (3.6) 1 (1.6) 4 (2.7)
3 80 (95.2) 58 (93.6) 138 (94.5) 0.4
Peri-procedural complications
Hematoma 3 (3.6) 3 (4.8) 6 (4.1) 0.7
Stroke/TIA 1 (1.2) 0 (0) 1 (0.7) 0.6
MI 1 (1.2) 3 (4.8) 4 (2.7) 0.2
Afib 1 (1.2) 1 (1.6) 2 (1.5) 0.8
Need for external electric shock 1 (1.2) 3 (4.8) 4 (2.7) 0.3
Bradi-arrhythmia 3 (3.6) 7 (11.3) 10 (6.9) 0.1
Death during PCI 1 (1.2) 2 (3.2) 3 (2) 0.6
CIN* 9 (16.4) 5 (13.2) 14 (15.1) 0.8

Procedural characteristics according to the type of implanted in patients with unprotected left main coronary artery disease (PCI – percutaneous coronary intervention; IABP – intra-aortic balloon pump; LAD – left anterior descending artery; LCX – left circumflex artery; POT – proximal optimization technique; KBPD – kissing balloon post dilatation; TKBPD – triple kissing balloon post dilatation; MV – main vessel; SB – side branch; iFR - instantaneous wave-free ratio; IVUS – intravascular ultrasound)

Balloon-expandable stents Self-apposing stents Total p value
Time from coronary angiogram to PCI, days (median, IQR) 2 (0–22.5) 2.5 (0–20) 2 (0–20) 0.8
Arterial acces site
Femoral 81 (96.4) 50 (80.6) 131 (89.7) 0.004
Radial 3 (3.6) 12 (19.4) 15 (10.3) 0.004
Pre-PCI IABP 5 (5.9) 1 (1.6) 6 (4.1) 0.2
Guide catheter
6F 47 (55.9) 31 (50) 78 (53.4)
7F 37 (44.1) 29 (46.8) 66 (45.2)
8F 0 (0) 2 (3.2) 2 (1.4) 0.2
Rotational atherectomy 2 (2.4) 1 (1.6) 3 (2.1) 0.6
Two stent technique 35 (41.7) 25 (40.3) 0.5
Provisional stenting 1 (3.1) 0 (0) 1 (1.7)
TAP 10 (31.2) 10 (40) 20 (35.1)
Minicrush 14 (43.7) 4 (16) 18 (31.6)
DK-Crush 3 (9.4) 0 (0) 3 (5.3)
Cullotte 3 (9.4) 10 (40) 13 (22.8)
V-stenting 1 (3.1) 1 (4) 2 (3.5) 0.03
MV predilatation 62 (78.5) 49 (79) 111 (78.7) 0.5
SB predilatation* 29 (40.9) 19 (30.7) 48 (36.1) 0.4
Predilatation at nominal pressure** 21 (30.4) 24 (46.1) 40 (36) 0.3
Dissection 19 (26.4) 9 (17.3) 26 (23.4) 0.2
POT* 57 (81.4) 28 (45.2) 87 (64.4) <0.001
POT after first stent*** 46 (78) 22 (78.6) 68 (50.4) 0.6
POT after KBPD*** 32 (54.2) 6 (21.4) 38 (28.2) 0.005
POT balloon diameter*, mm (median, IQR) 4 (4–4.5) 4 (4–4.5) 4 (4–4.5) 0.9
KBPD* 42 (62.7) 19 (30.6) 62 (45.9) <0.001
TKBPD* 5 (7.2) 0 (0) 5 (3.7) 0.03
MV stent diameter
3 14 (16.7) 18 (29.3) 32 (21.9)
3.5 53 (63.1) 44 (71) 97 (66.4)
4 17 (20.2) 0 (0) 17 (11.6) <0.001
MV stent length, mm (median, IQR) 24 (16–29) 22 (18–25) 22 (18–28)
SB stent diameter, mm (median, IQR) 3 (3–3.5) 3.5 (3–3.5) N/A 0.5
SB stent length, mm (median, IQR) 19 (13–23) 22 (18–27) N/A 0.06
Under expansion of >30% 6 (7.1) 8 (12.9) 14 (9.6) 0.3
IFR used pre-PCI 2 (2.4) 4 (6.5) 6 (4.1) 0.4
IFR used post-PCI 0 (0) 4 (6.5) 4 (2.8) 0.03
IVUS used pre-PCI 2 (2.4) 0 (0) 2 (1.4) 0.5
IVUS used post-PCI 12 (14.3) 14 (22.6) 26 (17.8) 0.3

Demographic and baseline clinical characteristics according to the type of the implanted stent in patients with unprotected left main coronary artery disease (ACS – acute coronary syndrome; NSTEMI – non-ST segment elevation myocardial infarction; STEMI – ST segment elevation myocardial infarction; PCI – percutaneous coronary intervention; TIA – transient ischemic attack; COPD - chronic obstructive pulmonary disease; PAD – peripheral artery disease; LBBB – left bundle branch block; RBBB – right bundle branch block; LVEF – left ventricular ejection fraction; HB – hemoglobin)

Balloon-expandable stents Self-apposing stents Total p value
Age, y (median, IQR) 63 (56–72) 62 (52–70) 63 (55–71) 0.2
Male 58 (69.1) 44 (71) 102 (69.9) 0.8
Cardiovascular risk factors
Hypertension 71 (84.5) 51 (83.6) 0.5
Dyslipidemia 73 (86.9) 53 (86.9) 126 (86.9) 0.6
Diabetes 25 (29.8) 17 (27.9) 42 (29) 0.8
Obesity 21 (25) 17 (27.4) 38 (26) 0.8
Smoking status
Active smoker 25 (30.1) 18 (29.5) 43 (29.9) 0.8
Former smoker 16 (19.3) 10 (16.4) 26 (18.1) 0.8
Patient history
ACS 32 (38.1) 26 (42.6) 58 (40) 0.6
Unstable angina 3 (9.4) 3 (11.5) 6 (10.3)
NSTEMI 11 (34.4) 5 (19.2) 16 (27.6)
STEMI 18 (56.2) 18 (69.3) 36 (62.1) 0.4
PCI 20 (23.8) 14 (22.6) 34 (23.3) 0.5
Atrial fibrillation 11 (13.1) 8 (13.1) 19 (13.1) 0.6
Stroke/TIA 10 (11.9) 5 (8.1) 15 (10.3) 0.6
Bleeding 2 (2.4) 3 (4.9) 5 (3.4) 0.6
COPD 1 (1.2) 1 (1.6) 2 (1.4) 0.7
PAD 21 (25) 4 (6.6) 25 (17.2) 0.004
Neoplasm 9 (10.7) 0 (0) 9 (6.2) 0.01
Clinical presentation
Stable angina 40 (47.6) 30 (48.4) 70 (47.9)
Unstable angina 19 (22.6) 11 (17.7) 30 (20.5)
NSTEMI 9 (10.7) 7 (11.3) 16 (11)
STEMI 10 (11.9) 8 (12.9) 18 (12.3)
ACS with cardiogenic shock 6 (7.2) 6 (9.7) 12 (8.2) 0.9
Atrial fibrillation 7 (8.6) 5 (8.1) 12 (8.4) 0.6
LBBB 6 (7.4) 3 (4.8) 9 (6.3) 0.4
RBBB 7 (8.6) 4 (6.4) 11 (7.7) 0.4
Ventricular tachycardia 0 (0) 2 (3.2) 2 (1.4) 0.2
LVEF, % (median, IQR) 50 (35–55) 50 (38–60) 50 (35–57.5) 0.6
LV systolic disfunction
None (>=50%) 42 (50.6) 32 (52.5) 74 (51.4)
Mild (40–49%) 16 (19.3) 13 (21.3) 29 (20.1)
Moderate (30–39%) 15 (18.1) 10 (16.4) 25 (17.4)
Severe (<30%) 10 (12) 6 (9.8) 16 (11.1) 0.9
Diastolic disfunction 71 (92.2) 49 (84.4) 120 (88.9) 0.2
Regional wall motion abnormality 58 (71.6) 38 (62.3) 96 (67.6) 0.3
LV aneurysm 5 (6.1) 4 (6.6) 9 (6.3) 0.6
LV thrombus 2 (2.4) 0 (0) 2 (1.4) 0.5
LV hypertrophy 31 (41.3) 14 (24.6) 45 (30.1) 0.06
Dilated cardiomyopathy 4 (4.8) 3 (4.9) 7 (4.9) 0.6
Mitral regurgitation
None/Trivial 12 (14.5) 2 (3.3) 14 (9.8)
Mild 51 (61.4) 45 (75) 96 (67.1)
Moderate 12 (14.5) 10 (16.7) 22 (15.4)
Severe 8 (9.6) 3 (5) 11 (7.7) 0.09
Aortic regurgitation
None/Trivial 61 (73.5) 40 (66.7) 101 (70.6)
Mild 15 (18.1) 20 (33.3) 35 (24.5)
Moderate 7 (8.4) 0 (0) 7 (4.9)
Severe 0 (0) 0 (0) 0 (0) 0.01
Ascending aorta diameter, mm (median, IQR) 32 (30–34) 34 (31–37) 32 (30–35) 0.02
Moderate/severe aortic stenosis 3 (3.6) 0 (0) 6 (4.2) 0.3
Tricuspid regurgitation 50 (60.2) 40 (65.6) 90 (62.5) 0.6
Pulmonary hypertension 15 (20) 4 (7) 19 (14.4) 0.04
Blood samples pre-PCI
HB, g/dl (median, IQR) 13.4 (12.2–14.4) 13.9 (12.5–15) 13.5 (12.3–14.7) 0.1
CK-MB, U/L (median, IQR) 25 (18–63) 22 (16–37) 22 (17–50) 0.2
Troponin, ng/ml (median, IQR) 0.24 (0.03–1.3) 1 (0.07–4.8) 0.3 (0.03–2.9) 0.2
Creatinine, mg/dl (median, IQR) 0.9 (0.8–1.2) 0.9 (0.8–1.2) 0.9 (0.8–1.2) 0.9
Creatinine clearance, ml/min/1.73m2 (median, IQR) 80 (62–97) 80 (65–95) 80 (64–96) 0.9
eISSN:
2734-6382
Language:
English